1. 2 Epidemiology of Diabetes CLASSIFICATION DIAGNOSIS/SCREENING PREVENTION/DELAY OF DM TODAYS...
-
Upload
wesley-dean -
Category
Documents
-
view
218 -
download
1
Transcript of 1. 2 Epidemiology of Diabetes CLASSIFICATION DIAGNOSIS/SCREENING PREVENTION/DELAY OF DM TODAYS...
1
Epidemiology of DiabetesCLASSIFICATION DIAGNOSIS/SCREENING PREVENTION/DELAY OF DM
TODAYS MISSIONTODAYS MISSION
Epidemiology of Diabetes
Definition
Diabetes – The term diabetes mellitus describes a metabolic disorder of multiple aetiology which is characterized by hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action or both.
DiabetesPrimary Goal for 2010
• Through prevention programs, reduce the disease incidence, its complications and its economic impact, in addition, to improve quality of life for all those persons that had diabetes or that are at risk to develop the disease.
5
Reference: U.S. Department of Health and Human Services. Healthy People 2010: Understanding and Improving Health. 2nd ed. Washington, DC: U.S. Government Printing Office, November 2000.
Epidemiology• The worldwide prevalence of DM has risen dramatically over
the past two decades, from an estimated 30 million cases in 1985 to 285 million in 2010. International Diabetes Federation projects that 438 million individuals will have diabetes by the year 2030 .
• Prevalence of both type 1 and type 2 DM is increasing worldwide, the prevalence of type 2 DM is rising much more rapidly, presumably because of increasing obesity, reduced activity levels as countries become more industrialized, and the aging of the population.
6
The magnitude of the healthcare problem of type 2 diabetes results not just from the disease itself but also from its association with obesity and cardiovascular risk factors, particularly dyslipidaemia and hypertension.
Type 2 diabetes has now been recognized as one manifestation of the “metabolic syndrome”, a condition characterized by insulin resistance and associated with a range of cardiovascular risk factors.
7
Various cardiovascular risk factors, including
hypertension and dyslipidaemia become
progressively worse with progression from normal
glucose tolerance to IGT/IFG to diabetes.
8
While there is good evidence for a strong genetic contribution to both obesity and diabetes, the increase in these conditions in both developed and developing countries appears to be due to a changing balance between energy intake and energy expenditure through physical activity.
Physical activity levels have probably diminished by half.
9
The tendency for the increased prevalence of type 2 diabetes to be concentrated in lower socioeconomic groups in developed countries and higher socioeconomic groups in developing countries probably reflects the adoption of a “healthier” lifestyle by better educated people in developed countries, while it is generally the affluent in developing countries who enjoy a high calorie intake and low level of physical activity.
10
• Approximately 1.6 million individuals (>20 years) were newly diagnosed with diabetes in 2010. DM increases with aging.
• In 2010, the prevalence of DM in the United Sates was estimated to be 0.2% in individuals aged <20 years and 11.3% in individuals aged >20 years.
• In individuals aged >65 years, the prevalence of DM was 26.9%.
• The prevalence is similar in men and women throughout most age ranges (11.8% and 10.8%, respectively, in individuals aged >20 years).
11
• In Asia, the prevalence of diabetes is increasing rapidly and the diabetes phenotype appears to be different from that in the United States and Europe—onset at a lower BMI and younger age, greater visceral adiposity, and reduced insulin secretory capacity.
12
• Diabetes is a major cause of mortality, but several studies indicate that diabetes is likely underreported as a cause of death. In the United States, diabetes was listed as the seventh leading cause of death in 2007; a recent estimate suggested that diabetes was the fifth leading cause of death worldwide and was responsible for almost 4 million deaths in 2010 .
13
14
Global Prevalence of Diabetes
Global Prevalence Estimates, 2000 and 2030
0.0% 1.0% 2.0% 3.0% 4.0% 5.0%
2000
2030 4.4 %
2.8 %
Reference: Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Diabetes Care. 2004; 27(5): 1047-1053.
Diabetes in the World
16
millions
India
31.731.7
China
20.820.8
USA
17.717.7
Indonesia
8.48.4
Japan
6.86.8
YearYear20002000
Reference: Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Diabetes Care. 2004; 27(5): 1047-1053.
Diabetes in the World
17
millions
India
79.479.4
China
42.342.3
USA
30.330.3
Indonesia
21.321.3
Japan
8.98.9
YearYear20302030
Reference: Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Diabetes Care. 2004; 27(5): 1047-1053.
18
Prevalence of Diabetes in Adults United States, BRFSS* 1998 - 2003
19
* BRFSS = “Behavioral Risk Factor Surveillance System” (>18 years). Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System 1998-2003. Atlanta, GA: United States, Department of Health and Human Services.
Prevalence of Diabetes by Sex and Year, Puerto Rico BRFSS* 1997, 2001 - 2003
20* BRFSS = “Behavioral Risk Factor Surveillance System” (>18 years). Centers for Disease Control and Prevention. Behavioral
Risk Factor Surveillance System 1997-2003. Atlanta, GA: United States, Department of Health and Human Services.
0
2
4
6
8
10
12
14
16
18
20
1988-94
2005-06
1988-94
2005-06
1988-94
2005-06
1988-94
2005-06
Undiagnosed
Diagnosed
0
2
4
6
8
10
12
14
16
18
20
1988-94
2005-06
1988-94
2005-06
1988-94
2005-06
1988-94
2005-06
Undiagnosed
Diagnosed
Overall Non-HispanicWhites
Non-HispanicBlacks
Mexican-Americans
Cowie et al., 2008;
Prevalence of Total Diabetes (diagnosed and undiagnosed diabetes) in the U.S. Adult Population, age ≥ 20,
1988-1994 to 2005-2006
Problem Statement
Iceberg Disease
Increased prevalence in newly industrialized and developing countries.
Disease acquired in the most productive period of their life.
Iceberg Disease
Increased prevalence in newly industrialized and developing countries.
Disease acquired in the most productive period of their life.
Undiagnosed or inadequately treated patients develop multiple chronic complications.
Lack of awareness about interventions for prevention and management of complications.
Undiagnosed or inadequately treated patients develop multiple chronic complications.
Lack of awareness about interventions for prevention and management of complications.
25
26
Eastern Mediterranean Health Journal, Vol. 15, No. 3, 2009 591
العدد ٢٠٠٩ عشر، الخامس المجلد العالمية، الصحة منظمة المتوسط، لشرق الصحية المجلة ،٣
Prevalence of type 2 diabetes in the
Islamic Republic of Iran: systematic
review and meta-analysisA.A Haghdoost,1,2 M. Rezazadeh-Kermani,1 B. Sadghirad 3 and H.R. Baradaran4
27
Province Prevalence • Bushehr 12.62 (7.62–17.63)• Qazvin 13.09 (7.93–18.25)• Gilan 5.45 (1.78–9.13)• Isfahan 8.20 (5.23–11.17)• Kerman 13.16 (7.55–18.77)• Khorasan 9.09 (2.28–15.89)• Kordestan 3.35 (0–7.36)• Tehran 7.43 (4.04–10.81)• Yazd 14.01 (10.75–17.27)28
• Prevalence of diabetes in IRAN Year 2000 2030Diabetic patients 2,103,000 6,421,000
• Prevalence of diabetes in Yazd ProvinceYear 2000 2030Diabetic patients 145,000 442,722
29
Prevalence of Diabetes in People aged ≥30 years: The Results of
Screening Program of Yazd Province, Iran, in 2012
Cross-sectional study , 2012.14993 subjects were randomly selected and
enquired by a pretested questionnaire. • Prevalence rate of known diabetes and
impaired fasting glucose was 16.3% & 11.9% respectively.
Journal of Research in Health Sciences 2014.
30
• Female gender, increasing age, high blood pressure, increased BMI and positive family history, are independent risk factor for diabetes.
31
DiagnosisDiagnosisand Type of Diabetesand Type of Diabetes
32
Definition
Diabetes – The term diabetes mellitus describes a metabolic disorder of multiple aetiology which is characterized by hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action or both.
Diagnosis
Fasting plasma glucose
HgbA1C
Oral glucose tolerance test (75 gram)
Specific Criteria
FPG 126 on two separate occasions
A1C ≥ 6.5%
Symptoms of hyperglycemia and a casual plasma glucose 200
2hr plasma glucose 200 during OGTT
Classification
Type 1 Diabetes Type 2 Diabetes Other Specific Types Gestational Diabetes
Type 1 Diabetes
ß-cell destruction, leading to absolute insulin deficiency
Immune-mediated diabetes(common)
Idiopathic
Type 1 Diabetes
Insulitis
Pathogenesis of Type 1 DM
Genetic HLA-DR3/DR4
Environment ? Viral infe..??
Type 1 DM
May range from predominantly insulin
resistance to predominantly an insulin
secretory defect
Type 2 Diabetes
Type 2 Diabetes
Loss of ß-cells Amyloid deposits
Hyalinization
Pathogenesis of Type 2 DM
ß cell defect Genetic
Secretory Defect Insulin resistance
May require Insulinß cell exhaustion
Other Specific Types
A. Genetic defects in Beta Cell Function/ Insulin secretionB. Genetic defects in Insulin ActionC. Diseases of the Exocrine PancreasD. EndocrinopathiesE. Drug or Chemical InducedF. InfectionsG. Uncommon Immune formsH. Genetic Syndromes with Diabetes
Diseases of the pancreas
Acquired causes include Pancreatitis, Trauma, infection, panreatectomy, and pancreatic
carcinoma.
Fibrocalculous pancreatopathy
Cystic fibrosis and Hemochromatosis
Secondary DMSecondary DMSecondary causes of Diabetes mellitus include :
Acromegaly
Cushing syndrome
Thyrotoxicosis
Pheochromocytoma
Chronic pancreatitis
Pancreatic Cancer
Secondary causes of Diabetes mellitus include :
Acromegaly
Cushing syndrome
Thyrotoxicosis
Pheochromocytoma
Chronic pancreatitis
Pancreatic Cancer
Diagnosis of Gestational Diabetes
Diagnosis of Gestational Diabetes
Gestational diabetes mellitus (GDM)
(diabetes diagnosed during pregnancy
that is not clearly overt diabetes)
Screening for and diagnosis of GDM
Screening for and diagnosis of GDM
75-g OGTT, with plasma glucose measurement fasting and at 1 and 2 h, at 24–28 weeks of gestation in women not previously diagnosed
with overt diabetes.
OGTT : Morning after an overnight fast of at least 8 h.
75-g OGTT, with plasma glucose measurement fasting and at 1 and 2 h, at 24–28 weeks of gestation in women not previously diagnosed
with overt diabetes.
OGTT : Morning after an overnight fast of at least 8 h.
Screen women with GDM for persistent
diabetes at 6–12 weeks post partum , using
the OGTT and non pregnancy diagnostic
criteria.
Women with a history of GDM should
have lifelong screening for the development
of diabetes or pre diabetes at least every 3
years.
Screen women with GDM for persistent
diabetes at 6–12 weeks post partum , using
the OGTT and non pregnancy diagnostic
criteria.
Women with a history of GDM should
have lifelong screening for the development
of diabetes or pre diabetes at least every 3
years.
ScreeningScreeningWho should you screen?
Adults who are overweight (BMI>25) or obese(BMI >30) and have 1 or more additional risk factors
Routine testing for others not meeting criteria should begin at age 45
If normal repeat every 3 years or more frequently if risk status changes
Who should you screen?
Adults who are overweight (BMI>25) or obese(BMI >30) and have 1 or more additional risk factors
Routine testing for others not meeting criteria should begin at age 45
If normal repeat every 3 years or more frequently if risk status changes
Risk FactorsRisk Factorso Physical inactivityo 1st degree relative with diabeteso High risk ethnic groups(African-American, Latino-Asian- Amer , Pacific Islanders)o Women who delivered a baby >9lbs +GDMo Hypertensiono HDL<35 or TG >250o Women with PCOSo IGT or IFG on previous testingo Hx CVDo Severe obesity or acanthosis nigricans
o Physical inactivityo 1st degree relative with diabeteso High risk ethnic groups(African-American, Latino-Asian- Amer , Pacific Islanders)o Women who delivered a baby >9lbs +GDMo Hypertensiono HDL<35 or TG >250o Women with PCOSo IGT or IFG on previous testingo Hx CVDo Severe obesity or acanthosis nigricans
Screening for type 1 diabetesScreening for type 1 diabetes
Consider referring relatives of those
with type 1 diabetes for antibody testing for
risk assessment in the setting of a clinical
research study. (E)
Consider referring relatives of those
with type 1 diabetes for antibody testing for
risk assessment in the setting of a clinical
research study. (E)
People with type 1 diabetes present with acute symptoms of diabetes and markedly elevated blood glucose levels, and some cases are diagnosed with life threatening ketoacidosis.
Measurement of islet autoantibodies in relatives of those with type 1 diabetes identifies individuals who are at risk for developing type 1 diabetes.
People with type 1 diabetes present with acute symptoms of diabetes and markedly elevated blood glucose levels, and some cases are diagnosed with life threatening ketoacidosis.
Measurement of islet autoantibodies in relatives of those with type 1 diabetes identifies individuals who are at risk for developing type 1 diabetes.
Such testing ,coupled with education about
symptoms of diabetes and follow-up in an
observational clinical study, may allow earlier
identification of onset of type 1 diabetes
and lessen presentation with ketoacidosis
at time of diagnosis.
Such testing ,coupled with education about
symptoms of diabetes and follow-up in an
observational clinical study, may allow earlier
identification of onset of type 1 diabetes
and lessen presentation with ketoacidosis
at time of diagnosis.
Children-Type II ScreeningChildren-Type II Screening
Overweight(BMI>85% for age and sex, weight for height>85%, or weight > 120% of ideal for height)
Plus any 2 +
Initiate at age 10 or onset of puberty, q3yrs.
Overweight(BMI>85% for age and sex, weight for height>85%, or weight > 120% of ideal for height)
Plus any 2 +
Initiate at age 10 or onset of puberty, q3yrs.
Fam Hx DMII 1st or 2nd deg relative. Nat Amer , Latino, Asian/Amer , Pacific Islander.
Signs of Insulin Resistance (HTN, Acanthosis Nigricans ,Dyslipidemia or PCOS or small-for-gestational age
birth weight). Maternal Hx of DM or GDM.
Initial EvaluationInitial Evaluation
Hx of complications: Microvascular: Retinopathy, Nephropathy, Neuropathy. Macrovascular: CHD , PAD , Cerebro- vascular disease.
Hx of complications: Microvascular: Retinopathy, Nephropathy, Neuropathy. Macrovascular: CHD , PAD , Cerebro- vascular disease.
PREVENTION/DELAY OF T2DM
PREVENTION/DELAY OF T2DM
PREDIABETESPREDIABETES Those patients with impaired fasting glucose (100-125) or impaired glucose tolerance
(2hr between 140-199)
Both are risk factors for future DM and cardiovascular disease.
Diet and Exercise…..how much? Follow up counseling important for success Metformin may be considered
Those patients with impaired fasting glucose (100-125) or impaired glucose tolerance
(2hr between 140-199)
Both are risk factors for future DM and cardiovascular disease.
Diet and Exercise…..how much? Follow up counseling important for success Metformin may be considered
THANKS
64
65
66
Prevalence of diabetes in the WHO South-East Asia Region
68
• Between 1996 and 2004. In those > 40 years the prevalence was 24% and it increased by 0.4% with each year after 20 years of age. The risk of type 2 diabetes was1.7% greater in women than men
69
Genetic defects of Insulin secretion
Maturity Onset Diabetes of the Young (MODY)
Six Genetic Ioci on different chromosomes have been identified to date.
Glucokinase related MODY(MODY 2) is common….but in India….HNF-4 alfa.
Usually Non ketotic / Non obese
Often in successive generations